This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Drug Delivery: Surveying The Global Competitive Landscape

NEW YORK, Dec. 12, 2012 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

Drug Delivery: Surveying the Global Competitive Landscape .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology

The importance of drug delivery technology grows ever more acute; commercial and industry interest is continuing to build. The benefits to patients can be seen in improved medical outcomes, while the pharmaceutical industry is able to extend patent protection through novel delivery regimes, bringing new therapies to the market that would, previously, have been impossible to administer.

This new, richly-detailed report provides the most comprehensive review of the sector and examines the competitive drug delivery landscape with analysis of 112 key companies. The company landscape is always on the move: some have been bought by the big players, whilst others have just run out of money and gone to the wall. Slowly but surely the private equity groups - most of whom have been in relative hibernation for the past couple of years - are gradually returning to the fold and kick-starting the impetus for capital investment.

This report provides you with key data for each featured company...

Company Overview & Technology Focus

Key Personnel

Competition & Competing Products

Key Milestones


R&D & Research Strategy

Key Agreements & Alliances

Financial Data (where available)

Comprehensive Contact Details

The ability to readily assess the companies involved, research areas of interest, products being developed, strategic collaborations and performance is key to understanding this market. In 670+ information-packed pages, this new report Drug Delivery: Surveying the global competitive landscape 2012 (published February 2012) evaluates companies large and small from multinationals to specialist development and technology businesses. All major technology areas such as Controlled-release, Nucleic acid, Nano-enabled and Targeted delivery are covered.

Related Publications

1 of 11

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs